Response to: 'Correspondence on ': hydroxychloroquine, COVID-19and the role of the rheumatologist' by Graef ' by Lo .
作者信息
Duarte-García Ali, Graef Elizabeth R, Liew Jean W, Konig Maximilian F, Kim Alfred Hyoungju, Sparks Jeffrey A
机构信息
Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
COVID-19 Global Rheumatology Alliance, Boston, Massachusetts, USA.
出版信息
Ann Rheum Dis. 2022 Aug 11;81(9):e164. doi: 10.1136/annrheumdis-2020-218680.
Abstract
摘要
相似文献
1
Response to: 'Correspondence on ': hydroxychloroquine, COVID-19and the role of the rheumatologist' by Graef ' by Lo .对洛（Lo）就格雷夫（Graef）的《关于羟氯喹、2019冠状病毒病及风湿病学家的作用的通信》的回复。
Ann Rheum Dis. 2022 Aug 11;81(9):e164. doi: 10.1136/annrheumdis-2020-218680.
2
Correspondence on ': hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef .关于格雷夫的《羟氯喹、2019冠状病毒病及风湿病学家的作用》的通信
Ann Rheum Dis. 2022 Aug 11;81(9):e163. doi: 10.1136/annrheumdis-2020-218589.
3
: hydroxychloroquine, COVID-19 and the role of the rheumatologist.羟氯喹、2019冠状病毒病与风湿病学家的作用
Ann Rheum Dis. 2020 Jun;79(6):734-736. doi: 10.1136/annrheumdis-2020-217480. Epub 2020 Apr 15.
4
Response to: 'Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian ' by Notz .回复：“抗风湿药物、B细胞耗竭与重症COVID-19：关于Mathian等人‘17例长期接受羟氯喹治疗的系统性红斑狼疮患者的2019冠状病毒病（COVID-19）临床病程’的通信” 作者：诺茨
Ann Rheum Dis. 2022 Nov;81(11):e217. doi: 10.1136/annrheumdis-2020-218795. Epub 2020 Nov 25.
5
Hydroxychloroquine dosing in systemic lupus erythematosus: response to 'Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis by Costedoat-Chalumeau .系统性红斑狼疮中羟氯喹的给药：对“Costedoat-Chalumeau对Fanouriakis关于2019年欧洲抗风湿病联盟系统性红斑狼疮管理建议更新的评论”的回应
Ann Rheum Dis. 2020 Aug;79(8):e91. doi: 10.1136/annrheumdis-2019-215615. Epub 2019 Jun 14.
7
Commentary on Levine et al: Festina Lente (Rush Slowly).
J Sex Marital Ther. 2022;48(8):775-778. doi: 10.1080/0092623X.2022.2055686. Epub 2022 Mar 23.
8
Response to: 'Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients" by Fornaro ' by Agca .对阿格查（Agca）所著《对福纳罗（Fornaro）的<类风湿关节炎患者中胆固醇水平变化和疾病活动对不同算法估算的10年心血管风险的影响>的回应》的回应
Ann Rheum Dis. 2020 Sep;79(9):e106. doi: 10.1136/annrheumdis-2019-216407. Epub 2019 Oct 11.
9
Correspondence on 'classification criteria: time for a rethink 'by D Porter .关于D·波特所著《分类标准：是时候重新思考了》的通信
Ann Rheum Dis. 2023 Jul;82(7):e176. doi: 10.1136/annrheumdis-2020-218775. Epub 2020 Sep 16.
10
Response to: 'Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty by Pino .对皮诺（Pino）对普莱蒂（Pouletty）所著《与模仿川崎病的新型冠状病毒肺炎相关的儿童多系统炎症综合征（川崎病-新冠病毒肺炎）：一项多中心队列研究》的通信的回复。
Ann Rheum Dis. 2022 Aug 11;81(9):e160. doi: 10.1136/annrheumdis-2020-218614.
本文引用的文献
1
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).COVID-19 住院患者使用羟氯喹（无论是否联合使用阿奇霉素）导致 QT 间期延长的风险。
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
2
Correspondence on ': hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef .关于格雷夫的《羟氯喹、2019冠状病毒病及风湿病学家的作用》的通信
Ann Rheum Dis. 2022 Aug 11;81(9):e163. doi: 10.1136/annrheumdis-2020-218589.
3
A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic.一种基于药代动力学的方法，用于应对 COVID-19 大流行期间风湿病患者羟氯喹短缺的情况。
ACR Open Rheumatol. 2020 Aug;2(8):491-495. doi: 10.1002/acr2.11164. Epub 2020 Jul 29.
4
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.羟氯喹或联合阿奇霉素治疗轻中度 COVID-19。
N Engl J Med. 2020 Nov 19;383(21):2041-2052. doi: 10.1056/NEJMoa2019014. Epub 2020 Jul 23.
5
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.羟氯喹治疗非住院的 COVID-19 轻症成年患者：一项随机试验。
Ann Intern Med. 2020 Oct 20;173(8):623-631. doi: 10.7326/M20-4207. Epub 2020 Jul 16.
6
Effects of hydroxychloroquine treatment on QT interval.羟氯喹治疗对 QT 间期的影响。
Heart Rhythm. 2020 Nov;17(11):1930-1935. doi: 10.1016/j.hrthm.2020.06.029. Epub 2020 Jun 28.
7
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为 COVID-19 暴露后预防的随机试验。
N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.
8
Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.羟氯喹和阿奇霉素在 2019 冠状病毒病大流行中的应用经验：对 QT 间期监测的影响。
J Am Heart Assoc. 2020 Jun 16;9(12):e017144. doi: 10.1161/JAHA.120.017144. Epub 2020 May 28.
9
QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.QT 间期延长、尖端扭转型室性心动过速和 COVID-19 短期使用氯喹或羟氯喹导致的猝死：系统评价。
Heart Rhythm. 2020 Sep;17(9):1472-1479. doi: 10.1016/j.hrthm.2020.05.008. Epub 2020 May 11.
10
Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre .
Ann Rheum Dis. 2021 Mar;80(3):e30. doi: 10.1136/annrheumdis-2020-217923. Epub 2020 May 18.
Zotero 插件